Epithelial Ovarian Cancer research hub
4 indexed studies · 3 currently recruiting
- recruitingPHASE3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
This study is looking into a new drug, AZD5335, for women with advanced ovarian cancer that has become resistant to usual chemotherapy. It compares AZD5335 to existing treatments to see if it works better at controlling the cancer's growth.
United States · Australia · Belgium - active not recruitingPHASE3
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This study is for women with advanced ovarian cancer who've had their first treatment. It's testing if two medications, rucaparib and nivolumab, given after initial treatment, can help prevent the cancer from returning or growing. It compares these drugs to dummy treatments.
United States · Australia · Belgium - recruitingNA
Platino-resistance in Ovarian Cancer
This study looks at why some ovarian cancers don't respond well to standard chemotherapy. Researchers will collect information and samples from patients receiving treatment to better understand and improve future care for women with ovarian cancer.
France - recruitingPHASE2
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
The CATALINA-2 study is investigating a new drug called TORL-1-23 for women with advanced ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. It aims to see how safe and effective this new treatment is.
United States · Australia · Austria